As of Sep 23, 2026: fair value of DHTRF $23.01, price $12.95, upside +77.7%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DHTRF for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
33‑month range $7.20 – $12.95 · fair‑value band $12.58 – $23.01 · the $12.95 price screens below the $23.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow DHTRF in your weekly email
Every Wednesday you see whether DHTRF is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Stock analysis
DHTRF (DHTRF) currently trades at $12.95, while our model-based Fair Value estimate is $23.01, implying the stock looks roughly 43.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $13.44 per share, and 3 of the 9 models we run sit above the $12.95 price.
Bear case: the Dividend Discount group reads lowest at $4.99, and 6 of the 9 models stay below the price. Evidence for this calculation is medium.
Scenario range: $12.58 (bear) to $23.01 (bull), the price of $12.95 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DHTRF reported revenue of $153M in FY2025 versus $73.3M in FY2021, a compound +20.3%/yr. Reported net income was −$50.5M in FY2025.
Key figures
Market cap $713M · P/S ratio 3.56 · EPS (TTM) $−0.9000 · Dividend yield 3.1% · Net margin −32.9% · Return on equity −10.4% · Return on assets 4.2% · Operating margin 32.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 78%, DHTRF screens cheaper than that median.
Fair Value models
Bear $12.58Fair Value $23.01Bull $23.01
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
’21
’22
’23
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.2% a year for the price and +5.5% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside+78% · Top 25%
Profitability
Return on assets4% · Above median
Net margin (TTM)−25% · Bottom 25%
Operating margin (TTM)33% · Top 25%
Growth and dividend
Revenue growth18% · Top 25%
Dividend yield (TTM)3.1% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.63× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DHTRF Fair Value". https://www.fairvalue-calculator.com/stock/DHTRF
Frequently asked questions
Is DHTRF overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $23.01 versus a price of $12.95, about +78% upside (undervalued).
What is the fair value of DHTRF?
Our model-based fair value for DHTRF is $23.01 (as of Sep 23, 2026), built from audited fundamentals. The current price: $12.95.
What is the quality score of DHTRF?
DHTRF has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DHTRF?
Our model-based price target is the fair value of $23.01 (as of Sep 23, 2026) from 9 valuation models. Cautious scenario $12.58, optimistic scenario $23.01. It is a calculation from audited fundamentals, not an analyst target.
What is the DHTRF stock forecast for 2026?
Our models put fair value at $23.01, about +78% upside versus a price of $12.95 (undervalued). Cautious scenario $12.58, optimistic scenario $23.01. The calculation is refreshed regularly with new filings.
What is the revenue of DHTRF?
DHTRF reported trailing-twelve-month revenue of about $198M (latest available figure, as of Sep 23, 2026).
Does DHTRF pay a dividend?
DHTRF currently shows a dividend yield of about 3.09% relative to its recent price (as of Sep 23, 2026).
What growth is priced into DHTRF?
For today's price to be fair in a discounted-cash-flow model, DHTRF would have to grow free cash flow by +19.0 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +20.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of DHTRF use?
Our models discount DHTRF at 10.3 %: a base by market capitalisation (small), damped by beta 0.66, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DHTRF that is +19.0 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has DHTRF delivered so far?
Over the past 4 years revenue at DHTRF grew +20.3 % a year. The price currently implies +19.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DHTRF growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into DHTRF (+19.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DHTRF?
The free-cash-flow yield on the price is 3.08 %: that much free cash flow DHTRF produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DHTRF?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DHTRF it is $23.01 per share (as of Sep 23, 2026), against a price of $12.95. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is DHTRF stock overvalued or undervalued in 2026?
As of Sep 23, 2026, DHTRF trades below its calculated fair value: price $12.95, fair value $23.01, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DHTRF?
No. The price is what the market pays today ($12.95); the fair value is what the company's own numbers justify ($23.01). For DHTRF the two are $10.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is DHTRF worth?
The market values DHTRF at about $713M (market capitalisation, as of Sep 23, 2026). Per share that is $12.95; our models calculate a fair value of $23.01 per share.
What do the bullish and bearish scenarios say about DHTRF?
Our models span a range for DHTRF: cautious scenario $12.58, base $23.01, optimistic $23.01 per share (as of Sep 23, 2026, price $12.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DHTRF?
Balance-sheet figures for DHTRF (as of Sep 23, 2026): return on equity −10.4%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is DHTRF from its 52-week high?
DHTRF trades at $12.95, at its 52-week high of $12.95 and 35% above the low of $9.58 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $23.01 is for.
Which stocks are comparable to DHTRF?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DHTRF stock attractive at the current price?
The data as of Sep 23, 2026: price $12.95, calculated fair value $23.01 (+78%), Quality Score 38/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DHTRF calculated?
We run DHTRF through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $23.01, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. DHTRF currently trades 78 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DHTRF?
The closing price on Sep 23, 2026 was $12.95. Our model-based fair value is $23.01, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DHTRF right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. A fairly wide model range ($12.58 to $23.01) leaves room in how you read the outcome.
Key figures of DHTRF
How large is the market capitalisation of DHTRF?
The market capitalisation of DHTRF is $713M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DHTRF?
The price-to-sales ratio of DHTRF is 3.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DHTRF?
Earnings per share at DHTRF are $−0.9000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DHTRF?
The dividend yield of DHTRF is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DHTRF?
The net margin of DHTRF is −32.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DHTRF?
The return on equity (ROE) of DHTRF is −10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the return on assets of DHTRF?
The return on assets (ROA) of DHTRF is 4.2% (last twelve months). Profit relative to everything the company owns. Harder to inflate than return on equity because debt does not boost it.
What is the operating margin of DHTRF?
The operating margin of DHTRF is 32.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DHTRF?
Revenue at DHTRF is growing +18.3% versus a year earlier (3y avg +24.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DHTRF?
Earnings per share at DHTRF are growing +30.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DHTRF carry?
The net debt of DHTRF is $334M (fiscal year 2025, ≈ 15.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DHTRF in the live analysis
One click puts DHTRF on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026